← Back to Search

Alkylating agents

VS-6063 + Chemotherapy for Ovarian Cancer

Phase 1 & 2
Research Sponsored by Michael McHale
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration
Free of active infection requiring antibiotics (with the exception of uncomplicated UTI)
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
Approved for 10 Other Conditions
No Placebo-Only Group

Study Summary

This trial will test the safety and efficacy of the combination of VS-6063, carboplatin, and paclitaxel in patients with ovarian cancer.

Who is the study for?
This trial is for women with certain types of ovarian cancer that came back or didn't go away after platinum-based chemo. They must have completed this treatment within the last 6 months and can't have had more than two chemo treatments for the recurrence. Participants need to be free from infections, recovered from past treatments, not pregnant, and using birth control.Check my eligibility
What is being tested?
The ROCKIF Trial is testing a combination of VS-6063 (an experimental drug), carboplatin, and paclitaxel in treating ovarian cancer. Patients will take VS-6063 orally and receive infusions of carboplatin and paclitaxel to see if this regimen safely reduces cancer cells.See study design
What are the potential side effects?
Possible side effects include those common to chemotherapy like nausea, fatigue, hair loss, low blood counts leading to increased infection risk or bleeding problems. The experimental drug may also cause unknown side effects due to its status as not FDA-approved.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I stopped my hormone therapy for cancer at least a week ago.
I am not currently on antibiotics for an infection, except for a simple UTI.
I have recovered from recent cancer treatments with no major side effects.
My cancer is one of the specified types, like serous or clear cell adenocarcinoma.
My ovarian, fallopian tube, or peritoneal cancer came back within 6 months after platinum chemotherapy.
I have had 2 or fewer chemotherapy treatments for my recurring cancer.
I am a woman who can have children, have a negative pregnancy test, and use birth control.
I have had one platinum-based chemotherapy treatment for my cancer.
I have had one non-chemotherapy treatment for my recurring or persistent disease.
My bone marrow, kidneys, liver, and nervous system are functioning well.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective response rate (ORR)
To assess the safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (Measured Via Adverse Events)
Secondary outcome measures
To assess the toxicity and adverse event profile of VS-6063 plus paclitaxel and carboplatin chemotherapy (Measured Via Adverse Events)
To describe health-related quality-of-life (QoL) outcomes of patients receiving VS-6063 plus paclitaxel and carboplatin chemotherapy. (Measured Via Questionnaire)
overall survival (OS)
+1 more

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Defactinib (VS-6063) +Carboplatin/PaclitaxelExperimental Treatment3 Interventions
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Find a Location

Who is running the clinical trial?

Nine Girls AskUNKNOWN
Michael McHaleLead Sponsor
Verastem, Inc.Industry Sponsor
38 Previous Clinical Trials
2,408 Total Patients Enrolled
3 Trials studying Ovarian Cancer
351 Patients Enrolled for Ovarian Cancer

Media Library

Carboplatin (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT03287271 — Phase 1 & 2
Ovarian Cancer Research Study Groups: Defactinib (VS-6063) +Carboplatin/Paclitaxel
Ovarian Cancer Clinical Trial 2023: Carboplatin Highlights & Side Effects. Trial Name: NCT03287271 — Phase 1 & 2
Carboplatin (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03287271 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What clinical indications is VS-6063 commonly utilized for?

"Beyond its effectiveness in treating melanoma, VS-6063 has been shown to reduce the growth of neoplasm metastasis, lymphomas, and various types of sarcoma."

Answered by AI

Is access to this research project currently available for participants?

"Indeed, current information on clinicaltrials.gov specifies that this research is actively recruiting participants. The study was first published on February 6th 2018 and was last modified January 23rd 2020; the investigators are hoping to recruit 90 people at a single location."

Answered by AI

What further investigations have been conducted regarding the effects of VS-6063?

"In total, 1182 studies are currently underway studying the therapeutic potential of VS-6063. Of those active investigations, 332 have progressed to Phase 3 and span 68069 locations with a majority located in Shanghai."

Answered by AI

How extensive is the scope of this experimental program?

"Correct. According to clinicaltrials.gov, this medical trial is actively seeking participants from a single location and 90 people in total. The study was first posted on February 6th 2018 with the most recent update occurring January 23rd 2020."

Answered by AI

What are the essential goals of this trial?

"The objectives of this 4 year trial are to gauge the safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (as evaluated through adverse events), observe changes in health related quality-of-life among patients receiving treatment, document any toxicities that may arise from therapy, and record overall survival rates as per RECIST 1.1 standards."

Answered by AI
~13 spots leftby Feb 2025